A high bioavailability opioid depot precursor formulation comprising:a) a controlled-release matrix;b) at least oxygen containing organic solvent;c) at least one active agent selected from buprenorphine and salts thereof.Typically such a precursor formulation will form a depot composition upon administration to the body of a subject.